Featured News

Lupus

LuGENE® Lupus Test Launches to Predict Flares & Drug Targets: Press Release

LuGENE® Lupus Test Launches to Predict Flares & Drug Targets: Press Release

AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.

read more
New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus

New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus

AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before they happen and provide specific information about each individual’s disease abnormalities, leading to faster, evidence-based treatment.

read more

Dermatology

Nephrology

New test to identify, treat kidney disease

New test to identify, treat kidney disease

CLICK TO READ ARTICLE & VIEW VIDEO > By Felicity Taylor CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A local company says it has discovered a new way to identify and treat kidney disease. AMPEL BioSolutions is a precision medicine company that studies RNA and gene...

read more

Cardiology

New blood test could prevent premature death from heart attacks and stroke

New blood test could prevent premature death from heart attacks and stroke

You won’t find test tubes or chemicals at Ampel Biosolutions. Instead, the company uses computers to study huge amounts of medical information – to identify genes responsible for auto-immune, kidney, skin, neurologic and infectious diseases. Now, the firm says it’s got a blood test for cardiovascular events at an early age.

read more

Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans. 

read more
Experimental Blood Test Could Improve Fibromyalgia Treatment

Experimental Blood Test Could Improve Fibromyalgia Treatment

A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.

read more
Local company unveils blood test to find treatments for chronic pain

Local company unveils blood test to find treatments for chronic pain

A medical discovery has been made in Charlottesville that may help people who experience chronic pain, fatigue and brain fog. “This is a big problem. This is a clinical problem that is not addressed. And it’s a problem that tends to discount patients,” said CEO and Chief Medical Officer Peter Lipsky.

read more

Infections

Genomic tests help doctors treat COVID-19 and long COVID

Genomic tests help doctors treat COVID-19 and long COVID

With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.

read more

Pin It on Pinterest